Metastatic disease is a major cause of cancer mortality and many mechanisms that enable cancer cell dissemination remain to be discovered1. In order for a cancer cell to successfully metastasize, it must first invade through the stroma that surrounds a primary tumor, enter (intravasate) into the circulatory system, survive in transit, exit (extravasate) from the circulation, and lastly establish a viable colony at the distant organ site2. Intravasation and extravasation are thus crucial steps in the metastatic cascade, yet every cancer cell is not inherently adept at disrupting and migrating through endothelial junctions3. In fact, there are a series of unique selection pressures that surround cancer cell vascular invasion and the process can be further influenced by a variety of endogenous and exogenous factors4. For these reasons, techniques that probe the aggressive behavior of advanced stage cancer often focus on vascular invasive ability as a means to predict metastatic spread.
Various model systems exist to facilitate the study of cancer cell vascular invasion in vitro. The most used in vitro assays involve either transwell systems to assess cancer cell migration through an endothelial barrier5 or Electric Cell-Substrate Impedance Sensing (ECIS) technology to monitor the real-time disruption of an intact endothelial monolayer by cancer cells6. These assays typically lack the fluid dynamics and stromal factors that would otherwise impact cancer cell attachment to an endothelial wall. This issue is somewhat circumvented by perfusable vascular networks that arise from the 3D culture of endothelia with supporting stromal cells, and these 3D microfluidic systems now represent the forefront of current in vitro options7,8. Still, these approaches omit the robust microenvironment of a functional circulatory system and therefore only in part substitute for in vivo models.
The most widely used in vivo model of vascular invasion is the mouse, in which experimental metastasis assays are commonly performed because they occur on relatively short timescales and are generally indicative of metastatic ability9. These assays involve direct injection of cancer cells into circulation and therefore model the end stages of metastasis, namely extravasation and cancer cell colonization of organs. The experimental metastasis assays differ based on the site of cancer cell injection and the organs ultimately analyzed. In the first assay type, cancer cells are injected into the tail vein of mice and cancer cell seeding in the lungs is monitored10,11. The second assay involves performing intracardiac injections to direct metastatic seeding toward the bone microenvironment12-14, but also the brain15. In the third assay, cancer cells are injected into the spleen in order to permit colonization of the liver16 whereas the fourth delivery route into the carotid artery carries cancer cells to the brain17,18. Irrespective of the cancer cell delivery method, organ colonization is the accepted experimental endpoint and is generally determined via luminescence, histology, or PCR-based techniques. Despite the physiologic advantages of conducting experimental metastasis assays within a murine host, these experiments still require weeks to months to complete and analyze.
The zebrafish (Danio rerio) model has recently emerged as a new system to study cancer progression19,20, and allows for the assessment of cancer cell vascular invasion within a functional circulatory system over a much shorter timescale when compared with mice21-24. The method utilizes a transparent zebrafish strain that has its endothelia tagged with a green reef coral fluorescent protein reporter driven by the kdrl promoter, the zebrafish receptor for vascular endothelial growth factor25. In the assay, cancer cells are labeled with a red fluorescent marker and injected into the precardiac sinus of 2-day old embryos. Anywhere between 48 to 96 hr after the injection, cancer cells that have invaded out of the vasculature and into the caudal region of embryos can be scored efficiently on a fluorescent microscope. Here we apply the technique to a panel of commonly used human breast cancer cell lines to demonstrate stark differences in their vascular invasive ability. Furthermore, we demonstrate that changing the injection site to the embryo yolk sac allows for the study of heterogeneous cell interactions, as cancer cell populations can be differentially labeled with fluorescent dyes and injected into zebrafish embryos lacking fluorescent vasculature. In this latter assay, cancer cells that have invaded the yolk and intravasated into the vasculature are scored in the caudal region 24 to 48 hr after injection. Due to the effectiveness and convenience of this model, zebrafish are increasingly employed to rapidly test the vascular invasive ability of cancer cells under a physiologic setting.